1,721,053 research outputs found
Foresight, cognition, and long-term performance : insights from the automotive industry and opportunities for future research
Full text linkWe explore the relationship between foresight and managerial cognition and the contribution of foresight to the long‐term performance of organizations facing major sources of uncertainty. Our research setting is the automotive industry, a compelling research setting for illustrating and reflecting upon the role of foresight in strategic decision making, as the industry is currently experiencing major drivers of change and technological discontinuities. We carefully examined the most recent empirical and theoretical works in the field of foresight, by conducting a thorough literature review. We found that scholars and practitioners increasingly emphasize the ability of foresight to change the mental models of senior managers and the role of such ability in the long‐term adaptation to external changes. Overall, our study contributes to the development of a programmatic stream of research in the domain of foresight and future studies
Drug prices and value of oncology drugs in Italy
Full text linkObjective: The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement (P&R) decision-making process within the definition of oncology treatment costs in Italy. Methods: The study included all P&R dossiers submitted to the Italian Medicines Agency between July 2015 and December 2017. It prospectively collected the data of the P&R process starting from dossier submission up to the Italian Health Service reimbursement decision. The cost of treatment per patient was estimated using both the list price (“gross cost”) and the confidential net price (“net cost”) of drug packages and applied to the median duration of treatment. A 2-sample stage Heckman decomposition model was used to evaluate the potential role of efficacy data and other information available at the time of P&R decision making on the gross and net cost. Results: A total of 37 oncology drugs related to 58 therapeutic indications were analyzed. The multivariate model showed that the variation of progression-free survival is the only variable predictor statistically associated with treatment cost, but this effect was observed only when confidential net prices were used (P=.026). Conclusions: Considering the perspective of a developed country having a public healthcare service with a central reimbursement negotiation is determined a relevant reduction in the treatment cost purchased by public payers. This is a useful approach to guarantee the affordability of innovative oncology drugs and to contain public expenditures on healthcare. Furthermore, the negotiation of confidential discounts and agreement clauses in managed entry agreements seemed to reward oncology drugs displaying an added therapeutic benefit. © 2021 ISPOR–The Professional Society for Health Economics and Outcomes Researc
Social solidarity can compensate for income inequalities: the case of the public Italian healthcare service
No full textRecommended from our members
Hypolipidemic agents in chronic therapy: a compliance study in the Italian ASSET cohort (INV-70)
No full text
Recommended from our members
Rilevanza delle variazioni demografiche di farmaco-utilizzazione per il governo della spesa farmaceutica pubblica
No full text- …
